NET Patient Foundation Research Abstracts
NPF and NCRAS Public Health England partnership project has been compiling statistics on the incidence, prevalence and survival of NET patients in England using English cancer registry data, with an aim to also access Scottish, Welsh and Northern Irish cancer registry data to also get UK wide statistics.
We carried out four pieces of research in 2017, abstracts for which can be found below:
- The Incidence and Prevalence of Neuroendocrine Tumours in England.
- The 1- year survival rates for Neuroendocrine tumour patients in England.
- Metachronus primary cancers in Neuroendocrine tumour patients.
- Neuroendocrine Tumour patients experiences of support in the community setting across the treatment trajectory.
Presenting symptoms and delay in diagnosis of gastrointestinal and pancreatic Neuroendocrine tumours
Ileocolonic neuroendocrine tumours identified in the English bowel cancer screening programme
Self-reported side effects in neuroendocrine tumour (NET) patients prescribed somatostatin analogues – the role for specialist dietitians and nurses
- Assess what symptoms/side effects patients report on SSA’s.
- Assess the severity of symptoms/side effects reported by patients whilst on SSA’s.
- Produce recommendations on how to deal with symptoms commonly experienced by patients on SSA’s.
This study has been accepted to be published in the British Journal of Nursing.
Recent News
OPEN Health Want to Hear from You – Research Study
OPEN Health are conducting interviews to understand the experiences of people living with neuroendocrine tumours of the gastrointestinal system and pancreas (GEP-NETs). Select here to download the PDF.
New screening programme identifies clinical trial opportunities for neuroendocrine cancer patients
- We are often told by our community that it is difficult to find information on clinical trials, and that the information around clinical trials can be difficult to interpret and understand if you don't have a scientific or medical background. Even when information...
Rarecan Seeks Your Input on Genetic Analysis Services
Rarecan, in collaboration with its partners, is exploring the potential for offering genetic analysis services to aid in cancer treatment decisions and clinical trial eligibility. Advancements in technology have made genetic analysis of tumors increasingly...